Talphera, Inc. (TLPH) stock
TLPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.91−0.13 (-12.46%)
Close on Nov 13, 2026Market cap $47.03MP/E –Yield –
Talphera EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Talphera's EPS for the twelve months ending Sep 30, 2026 was -$0.21. For fiscal 2023 it was -$1.29, down 122.6% from the year before. The highest annual figure on record is $5.72 in fiscal 2022.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -$1.29 | -122.6% |
| FY2022 | Dec 31, 2022 | $5.72 | – |
| FY2021 | Dec 31, 2021 | -$5.86 | – |
| FY2020 | Dec 31, 2020 | -$9.40 | – |
| FY2019 | Dec 31, 2019 | -$13.40 | – |
| FY2018 | Dec 31, 2018 | -$16.20 | – |
| FY2017 | Dec 31, 2017 | -$22.00 | – |
| FY2016 | Dec 31, 2016 | -$19.00 | – |
| FY2015 | Dec 31, 2015 | -$12.00 | – |
| FY2014 | Dec 31, 2014 | -$18.20 | – |
| FY2013 | Dec 31, 2013 | -$11.80 | – |
| FY2012 | Dec 31, 2012 | -$30.20 | – |
| FY2011 | Dec 31, 2011 | -$23.20 | – |
| FY2010 | Dec 31, 2010 | -$436.80 | – |
| FY2009 | Dec 31, 2009 | -$698.60 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.05 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.06 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.04 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.06 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.11 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.10 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.10 | – |
| Q4 FY2024 | Dec 31, 2024 | -$0.07 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.13 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.15 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.16 | – |
| Q4 FY2023 | Dec 31, 2023 | -$0.25 | – |
| Q3 FY2023 | Sep 30, 2023 | -$0.08 | – |
| Q2 FY2023 | Jun 30, 2023 | -$0.40 | -104.7% |
| Q1 FY2023 | Mar 31, 2023 | -$0.75 | – |
| Q4 FY2022 | Dec 31, 2022 | -$0.89 | – |
| Q3 FY2022 | Sep 30, 2022 | -$0.94 | – |
| Q2 FY2022 | Jun 30, 2022 | $8.58 | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.19 | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.24 | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.40 | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.60 | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.60 | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.93 | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.00 | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.60 | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.00 | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.60 | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.20 | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.20 | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.40 | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.60 | – |
| Q3 FY2018 | Sep 30, 2018 | -$4.20 | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.00 | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.60 | – |
| Q4 FY2017 | Dec 31, 2017 | -$4.00 | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.60 | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.80 | – |
| Q1 FY2017 | Mar 31, 2017 | -$6.80 | – |
| Q4 FY2016 | Dec 31, 2016 | -$4.20 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?